David (Wei Fu) Li
Lawyers
Advises senior management and boards of directors on public company and corporate governance matters.
David advises senior management and boards of directors of publicly listed companies on a wide range of corporate governance matters, including director independence, board and committee composition and structure, board and corporate policies and practices, board evaluations, succession planning and NYSE and Nasdaq compliance. In addition, he helps companies navigate SEC reporting and compliance, shareholder proposals, shareholder activism and proxy advisory services.
Experience
Recent Work
- SOPHiA GENETICS $57.5 million follow-on offering
- Rhône Capital acquisition of Invacare
- Vistra $2.25 billion secured notes offering
- QXO $750 million follow-on offering
- Vistra $2 billion Cogentrix Energy bridge acquisition financing
- Immatics $125 million follow-on offering
- ADC Therapeutics $60 million private placement
- Vistra $2 billion secured notes offering
- TopBuild $750 million notes offering
- K. Hovnanian Enterprises $900 million high-yield senior notes offering
- Royalty Pharma $2 billion senior notes offering
- AeroVironment $1.6 billion stock and convertible notes offerings
- ADC Therapeutics $100 million private placement
- Circle $1.05 billion IPO
- QXO $1.495 billion common and depositary share offerings
- QXO $2.25 billion senior secured notes offering
Insights
Education
J.D., Harvard Law School
- magna cum laude
- Senior Editor, Harvard Law Review
B.Sc., Psychology, University of Toronto
Qualifications and admissions
- State of New York